ATE397621T1 - Hemmer der interaktion zwischen p53 und mdm2 - Google Patents

Hemmer der interaktion zwischen p53 und mdm2

Info

Publication number
ATE397621T1
ATE397621T1 AT97935511T AT97935511T ATE397621T1 AT E397621 T1 ATE397621 T1 AT E397621T1 AT 97935511 T AT97935511 T AT 97935511T AT 97935511 T AT97935511 T AT 97935511T AT E397621 T1 ATE397621 T1 AT E397621T1
Authority
AT
Austria
Prior art keywords
compounds
mdm2
interaction
human
inhibitors
Prior art date
Application number
AT97935511T
Other languages
English (en)
Inventor
David Lane
Volker Boettger
Angelika Boettger
Stephen Picksley
Heinz-Kurt Hochkeppel
Carlos Garcia-Echeverria
Patrick Chene
Pascal Furet
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614197.3A external-priority patent/GB9614197D0/en
Priority claimed from GBGB9707041.1A external-priority patent/GB9707041D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE397621T1 publication Critical patent/ATE397621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT97935511T 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2 ATE397621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614197.3A GB9614197D0 (de) 1996-07-05 1996-07-05
GBGB9707041.1A GB9707041D0 (en) 1997-04-07 1997-04-07 Inhibitors of the interaction between p53 and mdm2

Publications (1)

Publication Number Publication Date
ATE397621T1 true ATE397621T1 (de) 2008-06-15

Family

ID=26309649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935511T ATE397621T1 (de) 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2

Country Status (8)

Country Link
EP (1) EP0958305B1 (de)
JP (1) JP2001500365A (de)
AT (1) ATE397621T1 (de)
AU (1) AU3847997A (de)
CA (1) CA2259149A1 (de)
DE (1) DE69738754D1 (de)
NZ (1) NZ333609A (de)
WO (1) WO1998001467A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
WO1998051707A1 (fr) * 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides a structures cycliques et a effet restaurateur d'activite de la proteine p53 sur les mutants de ladite proteine
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (de) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Phenoxyessigsäure- und Phenoxymethyltetrazolderivate mit Antitumoraktivität
DE69922372T2 (de) * 1998-05-26 2005-12-15 Agency For Science, Technology And Research Polypeptide aus creb-binding-protein und verwandtem protein p300 für die verwendung bei der transkriptionsregulation
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040038902A1 (en) * 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
AU2004212928A1 (en) 2003-02-13 2004-09-02 Bioveris Corporation Deazaflavin compounds and methods of use thereof
CA2544223C (en) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8598127B2 (en) * 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
CN1957094A (zh) * 2004-04-22 2007-05-02 奥索-麦克尼尔药品公司 Hdm2－抑制剂复合物及其用途
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
CN102481369A (zh) * 2009-06-16 2012-05-30 东海大学 抗革兰氏阴性菌剂
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
MX2012002420A (es) 2009-08-26 2012-06-27 Novartis Ag Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2721007B1 (de) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl-isochinolinon-verbindungen
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
RU2646110C2 (ru) * 2011-11-09 2018-03-01 Мерц Фарма Гмбх Унд Ко. Кгаа Нейротоксины, проявляющие укороченную биологическую активность
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP2948453B1 (de) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
KR20160012197A (ko) 2013-05-28 2016-02-02 노파르티스 아게 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도
EA028175B1 (ru) 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
JP2016537384A (ja) 2013-11-21 2016-12-01 ノバルティス アーゲー ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用
MX2017003819A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
EP3294318A4 (de) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
CN112119085A (zh) 2017-12-15 2020-12-22 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109206474A (zh) * 2018-11-27 2019-01-15 青岛海洋生物医药研究院 一种线性肽合成方法
CA3130400A1 (en) * 2019-02-20 2020-08-27 Oncolyze, Inc. Hdm2 antibody for use in treating cancer
CN112266407B (zh) * 2020-09-28 2023-05-12 宁夏医科大学总医院 特异结合p53蛋白的七肽、编码基因、制备方法及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Also Published As

Publication number Publication date
WO1998001467A2 (en) 1998-01-15
EP0958305B1 (de) 2008-06-04
AU3847997A (en) 1998-02-02
NZ333609A (en) 2000-08-25
EP0958305A2 (de) 1999-11-24
DE69738754D1 (de) 2008-07-17
JP2001500365A (ja) 2001-01-16
CA2259149A1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
ES2157994T3 (es) Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
MXPA02011303A (es) Nueva composicion farmaceutica.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE60028970D1 (de) An her2 bindende peptidverbindungen
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0958305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee